**Supplementary Table 1.** Characteristics and metabolic profiles of patients treated with Olanzapine or Risperidone according to their plasma IGFBP-2 levels.

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Olanzapine (n = 42)** | | **Risperidone (n = 45)** | | | ***p* value** | | | | |
| IGFBP-2  ≤ 220 ng/mL  (n = 32) | IGFBP-2  > 220 ng/mL  (n = 10) | IGFBP-2  ≤ 220 ng/mL  (n = 30) | IGFBP-2  > 220 ng/mL (n = 15) | | Drugs  (D) | | IGFBP-2  (BP2) | | D x BP2 |
| IGFBP-2 (ng/mL) | 124.6 ± 48.6 | 320.0 ± 97.3 | 135.1 ± 51.2 | 323.6 ± 90.5 | | 0.66 | | **< 0.0001** | | 0.83 |
| **Medication** | | | | |  | |  | |  | |
| Dose (mg/d) | 12.2 ± 4.9 | 13.8 ± 6.6 | 2.7 ± 1.8 | 3.3 ± 1.6 | | **<0.0001** | | 0.25 | | 0.61 |
| Duration (mo) | 21.0 ± 11.4 | 19.0 ± 8.6 | 19.4 ± 11.7 | 21.8 ± 13.7 | | 0.83 | | 0.94 | | 0.44 |
| **Physical characteristics** | | | | |  | |  | |  | |
| Age (y) | 30.4 ± 9.6 | 36.1 ± 12.3 | 26.5 ± 7.7 | 32.3 ± 12.1 | | 0.11 | | **0.0187** | | 0.99 |
| Weight (kg) | 89.0 ± 15.4 | 74.7 ± 18.7 | 87.0 ± 16.8 | 75.8 ± 15.7 | | 0.57 | | **0.0299** | | 0.54 |
| Height (cm) | 176.4 ± 6.1 | 173.3 ± 6.8 | 175.2 ± 6.0 | 176.0 ± 6.3 | | 0.63 | | 0.44 | | 0.21 |
| Body mass index (kg/m2) | 28.6 ± 4.6 | 27.8 ± 5.1 | 28.2 ± 4.5 | 24.5 ± 5.0 | | 0.78 | | **0.0014** | | 0.97 |
| Waist circumference (cm) | 99.4 ± 12.4 | 89.4 ± 16.5 | 97.6 ± 12.1 | 88.1 ± 15.0 | | 0.62 | | **0.0032** | | 0.93 |
| Reported weight gain (kg) | 14.1 ± 8.9 | 5.3 ± 3.2 | 13.9 ± 12.6 | 9.0 ± 4.2 | | 0.57 | | **0.0299** | | 0.54 |
| **Psychiatric evaluation** | | | | |  | |  | |  | |
| Illness severity score (CGI) | 3.7 ± 1.3 | 4.5 ± 1.4 | 3.5 ± 1.3 | 3.5 ± 1.3 | | 0.06 | | 0.20 | | 0.18 |
| Illness improvement score (CGI) | 2.5 ± 0.9 | 2.8 ± 0.8 | 2.0 ± 0.7 | 2.5 ± 1.0 | | **0.0318** | | **0.0470** | | 0.62 |
| Global assessment of functioning (GAF) | 57.9 ± 12.17 | 54.2 ± 11.2 | 66.8 ± 14.8 | 64.2 ± 16.0 | | **0.0058** | | 0.34 | | 0.87 |
| **Lipoprotein-lipid profile** | | | | |  | |  | |  | |
| Cholesterol (mmol/L) | 4.94 ± 1.00 | 4.75 ± 0.94 | 4.64 ± 1.19 | 4.40 ± 1.04 | | 0.21 | | 0.41 | | 0.93 |
| LDL-cholesterol (mmol/L) | 3.12 ± 0.88 | 3.00 ± 0.95 | 2.80 ± 1.08 | 2.93 ± 0.87 | | 0.41 | | 0.98 | | 0.59 |
| HDL-cholesterol (mmol/L) | 0.89 ± 0.14 | 1.03 ± 0.22 | 1.04 ± 0.21 | 1.04 ± 0.21 | | 0.08 | | 0.09 | | 0.13 |
| Cholesterol/HDL-cholesterol | 5.71 ± 1.47 | 4.83 ± 1.57 | 4.66 ± 1.52 | 4.32 ± 1.23 | | **0.0296** | | 0.09 | | 0.45 |
| Triglycerides (mmol/L) | 2.22 ± 1.11 | 1.36 ± 0.56 | 1.51 ± 0.71 | 1.05 ± 0.34 | | **0.0127** | | **0.0015** | | 0.31 |
| Apolipoprotein B (g/L) | 1.08 ± 0.34 | 0.93 ± 0.26 | 0.94 ± 0.29 | 0.90 ± 0.23 | | 0.24 | | 0.20 | | 0.46 |
| Apolipoprotein A1 (g/L) | 1.07 ± 0.11 | 1.18 ± 0.21 | 1.16 ± 0.15 | 1.17 ± 0.19 | | 0.32 | | 0.13 | | 0.18 |
| LDL peak particle size (Å) | 251.8 ± 4.4 | 255. 2 ± 2.1 | 254.4 ± 4.6 | 256.2 ± 3.2 | | 0.07 | | **0.0103** | | 0.43 |
| **Metabolic profile** | | | | |  | |  | |  | |
| Fasting glucose (mmol/L) | 5.97 ± 0.76 | 5.76 ± 0.53 | 5.76 ± 0.61 | 5.61 ± 0.42 | | 0.23 | | 0.25 | | 0.84 |
| Fasting insulin (pmol/L) | 114.3 ± 66.5 | 77.2 ± 67.6 | 100.2 ± 65.4 | 64.5 ± 19.9 | | 0.36 | | **0.0151** | | 0.96 |
| HOMA-IR | 31.0 ± 20.9 | 20.6 ± 20.7 | 26.3 ± 18.7 | 16.2 ± 5.5 | | 0.31 | | **0.0233** | | 0.97 |
| Systolic blood pressure (mmHg) | 128.5 ± 11.6 | 125.8 ± 11.1 | 123.0 ± 11.2 | 117.1 ± 15.2 | | **0.0188** | | 0.15 | | 0.59 |
| Diastolic blood pressure (mmHg) | 84.3 ± 8.8 | 84.3 ± 8.2 | 81.9 ± 8.2 | 76.4 ± 12.2 | | **0.0249** | | 0.22 | | 0.22 |
| Heart rate (beats/min) | 68.7 ± 12.0 | 68.2 ± 14.3 | 66.4 ± 12.0 | 64.89 ± 10.5 | | 0.34 | | 0.74 | | 0.86 |

- All values are mean ± SD. Data analyzed by two-way ANOVA. Significant differences are shown in bold red.